{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.100","upperLimit":"24.000","value":"16.30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Time to progression was calculated as the time from the first dosing of study treatment to the first documented PD and assessed by the ESEC","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide 25 mg administered orally once daily (QD) until progressive disease or unacceptable toxicity","id":"OG000","title":"Lenalidomide"}],"paramType":"MEDIAN","populationDescription":"The EE population consisted of all participants who met basic protocol requirements (all eligibility criteria) and were evaluated after receiving at least one dose of lenalidomide","reportingStatus":"POSTED","timeFrame":"From day 1 of study treatment to the date of disease progression; up to data cut date of 19 May 2017; maximum study duration was 134.1 weeks","title":"Kaplan-Meier Estimate of Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"weeks"}